Genenta Science SpA · NASDAQ:GNTA
Genenta Science SpA — Investor Presentation (July 2026)
32 slides from Genenta Science SpA's investor presentation, July 2026
Slide 1: Genenta Evolving into Saentra Forge
GENENTA EVOLVING INTO SAENTRA FORGE The Next-Generation Strategic Industrial Consolidator in Aerospace, Defense, National Security and Biotech. © 2026 Genenta Science. All rights reserved worldwide July 2026
Slide 2: Forward-Looking Statements and Other Notices
FORWARD-LOOKING STATEMENTS AND OTHER NOTICES Statements in this presentation contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of histor
Slide 3: Genenta Transforming into Saentra Forge
GENENTA TRANSFORMING INTO SAENTRA FORGE In response to evolving market dynamics and opportunities, Genenta Science S.p.A. (Nasdaq: GNTA) is embarking on a strategic transformation to evolve into a next-generation industrial consolidator focused on acquiring privately held businesses operating in nat
Slide 4: The Strategic Pillars
THE STRATEGIC PILLARS The Company will be organized around key synergistic pillars built AEROSPACE DEFENSE NATIONAL BIOTECHNOLOGY SECURITY through strategic majority or full acquisitions, creating a diversified platform. 4
Slide 5: A Structural Advantage
A STRUCTURAL ADVANTAGE In strategically regulated sectors, the barrier that deters most buyers is our entry point not an obstacle, but a moat. 1: Fondazione Praexidia is a private-law foundation bringing together senior figures from Italian government institutions, the defense industry and the armed
Slide 6: Why Now: The Opportunity
WHY NOW: THE OPPORTUNITY Italy’s defense supply chain is a vast, fragmented base of SMEs – the headline figures capture only the tip 6
Slide 7: Why Now: The Opportunity
WHY NOW: THE OPPORTUNITY Strategic value is leaving Italy just as a capital and demand surge into the sector. Genenta turns that gap into a consolidation aggregator. 7
Slide 8: Acquisition Criteria
ACQUISITION CRITERIA A disciplined filter applied to strategic scale-up – acquiring where private capital wants in but cannot easily access. 8
Slide 9: Valuation Arbitrage
VALUATION ARBITRAGE The Genenta Science value creation model is based on multiple valuation arbitrage: acquiring companies at private market valuations, consolidating and accelerating their growth, and ultimately monetizing them through public market multiples through ownership in a Nasdaq-listed pl
Slide 10: Leadership
LEADERSHIP + 30 years of experience as Chief Financial Officer in various biopharmaceutical, Highly experienced executive with skills diagnostic, and life science companies, in strategic finance, restructuring and reorganization processes, internal including Biological Dynamics, GenMark Diagnostics
Slide 11: Aerospace & Defense
Genenta Science 2 * AEROSPACE get ¢ DEFENSE
Slide 12: Aerospace & Defense
AEROSPACE & DEFENSE Genenta’s defense and advanced manufacturing pillar will be built through the acquisition of multiple privately held businesses operating across defense, aerospace and security sectors. Through this integration, the Company will seek to enhance these businesses through operationa
Slide 13: Aerospace
Genenta Science 4. | * AEROSPACE
Slide 14: Why Space, Why Now: The Strategic Rationale
WHY SPACE, WHY NOW: THE STRATEGIC RATIONAL The space economy is scaling rapidly, driven by commercial demand national security priority and sovereign 14
Slide 15: Sophia High Tech: Company Overview
SOPHIA HIGH TECH: COMPANY OVERVIEW What it does • Builds the critical mechanical components of space and defense systems, precision parts that hold rockets together, protect satellites in orbit, and let aircraft perform under extreme stress. • Covers the entire product lifecycle: concept design & si
Slide 16: Sophia HT: Key Figures
SOPHIA HT: KEY FIGURES The transaction • April 22, 2026 — Genenta signed an Investment Agreement with Sòphia HT to reach a controlling stake through a phased two-tranche structure. • June 12, 2026 — Required Golden Power authorization obtained. • June 25, 2026 — First tranche completed following sat
Slide 17: Space Manufacturing
Genenta Science SPACE MANUFACTURING SIGN & ADDITIVE PETE RERON aT POWDER THERMAL SIONAL TESTING & PACKAGING & SIMULATION — MANUFACTURING REMOVAL TREATMENTS MACHINING WASHING CONTROL INSPECTION ‘SHIPMENT 17
Slide 18: Customers & Programs
Genenta Science esa ' ARIANE VEGA CUSTOMERS &PROGRAMS a Thal Ales <a . ry ox MILANI 2p es. fie Be, ‘Space Ridergt “ify Sa \ ai : | Sa wm a ION Carrier 7a GCAP ‘€ LEONARDO € LEONARDO § 4€ LEONARDO . 5) , fo] Aa INFN ThalesAlenia Ss. Air ft Pa) ae coke € LEONARDO
Slide 19: Defense
Genenta Science ° DEFENSE
Slide 20: Defense Market Context
Genenta 20 Science DEFENSE MABKETCONTEXT DEFENSE MARKET CONTEXT THE DEFENSE INDUSTRIAL BASE IS EXPANDING STRUCTURALLY Global defense spending is supported by sustained geopolitical priorities, long-term NATO commitments and unprecedented European industrial investment GLOBAL MILITARY EXPENDITURE (US
Slide 21: ATC: Company Overview
ATC: COMPANY OVERVIEW ▪ ATC “Armi Tattiche Custom” is an Italian company founded in 2019. ATC designs, engineers, and manufactures high-precision tactical rifles, chassis systems, optics mounts, bipods, and related accessories. Through vertical integration of design and through final quality assuran
Slide 22: ATC: The Acquisition
ATC: THE ACQUISITION • Timing: January 2026 — Initial investment agreement signed. May 2026 — Genenta completed the acquisition of 100% of A.T.C. S.r.l. ("ATC"). • 100% acquired with no cash consideration The acquisition was completed entirely through newly issued Genenta shares, preserving corporat
Slide 23: ATC: Key Figures
ATC: KEY FIGURES Financial profile • Revenues: ~€4.0M in 2026 → ~€9.0M by 2027. • EBITDA: >€2.0M in 2026, expected to approximately double in 20271. • Solid net cash position, no bank debt — disciplined management structure. 1: Based on management estimates and current order pipeline; not audited; s
Slide 24: Biotechnology
Genenta Science BIOTECHNOLOGY
Slide 25: Genenta: Developing a Potential First in Class Cell Therapy
GENENTA: DEVELOPING A POTENTIAL FIRST IN CLASS CELL THERAPY Temferon TM is a one-time cell therapy designed to break the tumor-induced Proprietary platform to immune suppression by enabling sustained targeted expression of therapeutic provide durable and payload inside the tumor microenvironment (TM
Slide 26: Survival Metrics in TEM-GBM Study up to 3 Years
SURVIVAL METRICS IN TEM-GBM STUDY UP TO 3 YEARS Evaluable Patients Dosed with Temferon 25 Number of Patients survival > 1 year 19 (76%) Number of Patients survival > 2 years1 8 (32%) Number of Patients survival > 3 years 2 (8%) Survival rate at 1 and 2 years since first surgery compared favorably wi
Slide 27: Partnerships to Take to the Next Stage
PARTNERSHIPS TO TAKE TO THE NEXT STAGE The Company has reached key clinical milestones that it believes may enable the advancement of its cell therapy platform through partnerships with leading pharmaceutical and biotech companies, with the potential to accelerate development, market access, and str
Slide 28: Preliminary Clinical Data in uMGMT GBM
PRELIMINARY CLINICAL DATA IN µMGMT GBM • Detectable and expectedly very low levels of IFN-⍺ (pg/ml range) in plasma; • Manageable safety profile, with adverse events commonly associated with autologous stem cell transplantation and glioblastoma; SAFETY AND • No dose limiting toxicities observed to d
Slide 29: Pierluigi Paracchi, CEO
PIERLUIGI PARACCHI, CEO pierluigi.paracchi@genenta.com www.genenta.com Via dell’Annunciata 31 - 20121 Milan, Italy © 2026 Genenta Science. All rights reserved worldwide
Slide 30: Appendix
APPENDIX © 2026 Genenta Science. All rights reserved worldwide
Slide 31: Board of Directors
BOARD OF DIRECTORS Francesco Dagnino is Founder and Riccardo Palmisano holds a degree in Managing Partner of LEXIA. Specialized Medicine. A manager with over 40 years of in M&A, private equity, venture capital, experience in the pharma and biotech and capital markets, he assists funds, sectors, with
Slide 32: Financial Profile
FINANCIAL PROFILE Cash & cash equivalents and marketable securities1 $ 33 MM Expected cash runway2 More than 12 months Number of shares outstanding3 48.2 MM Average daily volume4 1.5 MM shares 1 – December 31, 2025. 2 – For additional information see the Company’s Form 20-F filed with the SEC on Mar